|Bid||3.7200 x 1800|
|Ask||3.9400 x 1300|
|Day's range||3.5400 - 3.8150|
|52-week range||2.9650 - 15.3160|
|Beta (5Y monthly)||1.69|
|PE ratio (TTM)||N/A|
|Earnings date||08 Aug 2022 - 12 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||18.29|
Market forces rained on the parade of Ocular Therapeutix, Inc. ( NASDAQ:OCUL ) shareholders today, when the analysts...
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 12% and 12.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
BEDFORD, Mass., May 09, 2022--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported financial results for the quarter ended March 31, 2022, and provided updates on its ophthalmology pipeline.